Nupam Mahajan

Title: Nupam Mahajan: Innovator in Cancer Therapeutics

Introduction

Nupam Mahajan is a distinguished inventor based in Tampa, Florida, known for his significant contributions to cancer research and therapeutics. With a total of seven patents to his name, Mahajan has made strides in developing innovative methods for diagnosing and treating various types of cancer.

Latest Patents

Among his latest patents is an allosteric inhibitor of WEE1 kinase. This patent discloses a method for selecting a cancer therapeutic for a patient by assaying a tumor biopsy sample to detect PAXIP1 expression. If PAXIP1 is detected, a WEE1 inhibitor is selected as the appropriate cancer therapeutic. Another notable patent focuses on methods for diagnosing and prognosing epithelial tumors. This patent introduces a biomarker that can distinguish aggressive epithelial tumors in a tissue biopsy from normal, hyperplastic, and benign neoplastic tumors. It also identifies epithelial tumors that have developed resistance to hormone therapy, providing crucial methods for diagnosis and prognosis in patients suspected of having epithelial tumors, such as prostate tumors.

Career Highlights

Nupam Mahajan has worked with prominent institutions, including the H. Lee Moffitt Cancer Center and Research Institute and the University of Central Florida Research Foundation. His work in these organizations has been pivotal in advancing cancer research and therapeutic strategies.

Collaborations

Throughout his career, Mahajan has collaborated with notable colleagues, including Kiran N. Mahajan and Nicholas James Lawrence. These collaborations have further enriched his research and innovation in the field of cancer therapeutics.

Conclusion

Nupam Mahajan's contributions to cancer research through his patents and collaborations highlight his role as a leading innovator in the field. His work continues to pave the way for advancements in cancer diagnosis and treatment.